Table 2.
Costs and quality-adjusted life-years obtained for the base-case and scenario analyses
| Parameter | Base-case (GBP) | Base-case including dialysis and transplantation costs (GBP) | Scenario analysis of nonsignificant relative risk (0.714) of mortality (GBP) | Scenario analysis of adverse event costs (GBP) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PA21 | SC | Δ | PA21 | SC | Δ | PA21 | SC | Δ | PA21 | SC | Δ | |
| Drug costs | 12,969 | 14,590 | −1621 | 9845 | 11,086 | −1241 | 6818 | 7194 | −376 | 12,969 | 14,590 | −1621 |
| Adverse event costs | 150 | 138 | 12 | 114 | 105 | 9 | 79 | 68 | 11 | 2842 | 1561 | 1282 |
| Transplantation costs | – | – | – | 34,414 | 34,497 | −83 | 24,296 | 22,720 | 1576 | – | – | – |
| Dialysis costs | – | – | – | 87,552 | 87,773 | −220 | 60,956 | 56,926 | 4030 | – | – | – |
| Total costs | 13,119 | 14,728 | −1609 | 131,925 | 133,461 | −1536 | 92,149 | 86,908 | 5241 | 15,811 | 16,149 | −338 |
| QALYs | 2.826 | 2.835 | −0.009 | 5.045 | 5.057 | −0.012 | 3.545 | 3.313 | 0.232 | 2.826 | 2.835 | −0.009 |
Costs are rounded values
GBP Great Britain pound, PA21 sucroferric oxyhydroxide, SC sevelamer carbonate, QALYs quality-adjusted life-years